Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent, painful nodules, abscesses, and tunnels (sinus tracts), typically affecting areas such as the underarms, groin, and under the breasts. Over time, HS can lead to scarring, discomfort, and a significant impact on quality of life.
The condition is complex and often underdiagnosed, with causes linked to follicular occlusion, immune dysregulation, and genetic factors. Standard treatments—including antibiotics, anti-inflammatory medications, and biologics—may not always provide consistent or lasting relief for all patients.
Clinical trials play a critical role in advancing treatment options for hidradenitis suppurativa. At Rejuvenation Dermatology, our HS clinical trials focus on evaluating emerging therapies that target the underlying inflammatory pathways and disease progression.
Participants receive access to investigational treatments within a structured, medically supervised environment. Each study follows strict ethical and regulatory standards, ensuring patient safety while contributing to the development of more effective therapies.
Our goal is to reduce the frequency and severity of flare-ups, improve skin healing, and enhance overall quality of life for individuals living with HS.
STUDY INFO:
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa.
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy.
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa.
If you are interested in joining this study, please click here.
STUDY INFO:
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB (PF-06651600) IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA
If you are interested in joining this study, please click here.
EVIDENCE DRIVES BETTER HS TREATMENT
We believe hidradenitis suppurativa care should be guided by strong clinical evidence, not temporary symptom management. Our clinical trials are designed to evaluate advanced therapies that target underlying inflammation and disease progression, helping generate meaningful data that improves long-term outcomes.
RESEARCH INTEGRATED INTO REAL CLINICAL PRACTICE
All studies are conducted within active dermatology clinics, ensuring patients receive care in a familiar medical setting. Our dermatologists understand the physical and emotional burden of HS and approach treatment with both clinical precision and patient-centered care.
ETHICS ARE NON-NEGOTIABLE
Every hidradenitis suppurativa trial undergoes independent ethics board review before enrollment begins. Participants are fully informed, carefully screened, and monitored throughout the study, with safety protocols that meet and exceed regulatory standards.
STANDARDIZED, NATIONAL EXECUTION
Our multi-site research network operates under centralized oversight and standardized protocols, ensuring consistent study execution, high-quality data collection, and reliable outcomes across all locations.
Clinical research at Rejuvenation Dermatology is driven by a commitment to advance patient care through evidence-based medicine. Through participating in regulated clinical trials, the organization helps to shape development of safer, more effective dermatologic treatments while ensuring patients receive care that meets the highest ethical and scientific standards.
Participation in clinical research enables Rejuvenation physicians to remain at the forefront of dermatologic innovation and provides patients with access to therapies that may not yet be commercially available.
DERMATOLOGY-LED RESEARCH
Our HS trials are led by experienced dermatologists with expertise in complex inflammatory skin diseases. Physician oversight ensures every participant receives medically sound, research-driven care.
EXPERIENCE WITH COMPLEX CONDITIONS
Hidradenitis suppurativa requires specialized understanding and management. Our trials are designed to address moderate to severe cases, including patients who have not responded to conventional treatments.
SAFETY FIRST, ALWAYS
Patient safety is central to every study. Strict eligibility criteria, continuous monitoring, and adherence to Good Clinical Practice guidelines ensure a safe and controlled research environment.
CONSISTENT EXECUTION, TRUSTED RESULTS
Sponsors rely on our ability to deliver efficient recruitment and high-quality, audit-ready data. This structured approach ensures a seamless experience for participants.
ADVANCING FUTURE HS THERAPIES
Participation in clinical trials contributes to the development of new treatments that may shape the future of hidradenitis suppurativa care, improving outcomes for patients worldwide.
Participants may gain access to new therapies while receiving expert care.
Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that causes painful lumps and abscesses in areas where skin rubs together.
Yes, all treatments are carefully studied and monitored under strict medical and ethical guidelines.
HIDRADENITIS SUPPURATIVA CLINICAL TRIALS | CLINICAL TRIALS CANADA | REJUVENATION DERMATOLOGY
Rejuvenation Dermatology’s Clinical Trials Department is a national, multi-site research network dedicated to advancing dermatologic care through ethically conducted, regulated clinical research. Integrated within routine clinical practice, the department partners with global pharmaceutical sponsors to evaluate novel therapies and offers early access to innovative treatment options. The team supports industry-sponsored and investigator-initiated trials across a broad range of indications, collaborating closely with sponsors, CROs, investigators, and ethics boards to deliver high-quality data while maintaining a strong commitment to patient safety.
Since its inception, the division has evolved from a single research-focused clinic into a coordinated, multi-province research network. Today, it operates with standardized infrastructure, centralized oversight, and experienced investigators across Canada.
